During pregnancy, small amounts of fetal cell-free DNA that pass through the placenta can be detected in the mother’s blood. The non-invasive prenatal test (NIPT) screens this fetal DNA to identify the presence of alterations in the chromosomes of the baby. NIPT is the most reliable and safe prenatal screening option currently available, with no associated risks for either the mother or the fetus. From a single tube of mother´s blood, drawn as early as 10 weeks in the pregnancy, this test allows to determine if the future baby presents some of the most frequent chromosome alterations.
The non-invasive prenatal test (NIPT) in mother’s blood is a new prenatal screen test that allows to identify the presence of the most frequent fetal chromosome anomalies (aneuploidies in chromosomes 13, 18, 21, X and Y). This test represents a great advance in prenatal screening.
By carrying out a simple blood test from week 10 of pregnancy, remnants of fetal genetic material that pass through the placenta can be detected in the mother´s blood. From the study of this fetal material, it is possible to foresee the possibility that the future baby suffers from some of the most frequent chromosome alterations.
The non-invasive prenatal test requires 10 ml blood sample. Once drawn, it must be sent at room temperature to our laboratory where an extraction of both maternal and fetal genetic material will be performed. This material will be then analyzed using state-of-the-art Next Generation Sequencing (NGS) technology.
From the analysis of the sequencing results, the amount of fetal and maternal DNA present for each of the chromosomes analyzed will be determined and thus the probability that the fetus suffers from some of the most common aneuploidies can be elucidated.
Our results reports are available in 7 days after sample reception.
Medical societies have recommended NIPT as an option for all pregnant women regardless of age or risk1-2. This screening test is aimed at patients with gestation of 10 weeks or more with single or twin pregnancies. It is particularly beneficial for woman of advanced maternal age (≥ 35 years), who have had a positive result in serologies, an abnormal ultrasound or a medical history that suggests an increased risk for T21, T18 or T13, or aneuploidy of sex chromosomes.
Non-Invasive Prenatal Testing results are the most precise prenatal screening tests results currently available, more precise than the traditional combined screening of the first trimester3. In general, the probability of obtaining a false positive or false negative result is lower than in other tests1-3.
NIPT detects the main trisomies: Down syndrome, Patau syndrome and Edwards syndrome, with a sensitivity and specificity higher than 98% and 99% respectively. This test is also useful to detect aneuploidies in the sex chromosomes with sensitivity and specificity greater than 95% and 99% respectively1-3.
iGLS uses Verifi® non-invasive prenatal test (Illumina) to determine, by means of massive sequencing of the entire genome, the presence of the most common fetal aneuploidies. This test has significantly higher detection rates than traditional methods1-4 and has shown excellent detection rates and very low false positive rates compared to other non-invasive prenatal diagnosis methods5. Verifi® test has also the lowest published error rate in the market6-8.
1. Practice Bulletin No. 163. Obstet Gynecol. 2016; 127(5):979-981.
2. Gregg AR et al. Genet Med. 2016;18(10):1056-1065.
3. Bianchi DW et al. 2014;370(9):799-808.
4. Norton ME et al. N Engl J Med. 2015;372(17):1589-1597.
5. Gil MM et al. Ultrasound Obstet Gynecol. 2015;45(3):249-266.
6. Taneja PA et al. Prenat Diagn. 2016;36(3):237-243.
7. McCullough RM et al. PLoS One. 2014;9(10):e109173.
8. Ryan A et al. Fetal Diagn Ther. 2016;40(3):219-223.